IP38-11: Development and validation of a prognostic model to guide the optimal timing of Docetaxel after an Androgen Receptor Pathway Inhibitor in mCRPC

Saturday, May 16, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!